Lee JI - Search Results

1

Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.

Noh H, Jung SY, Kwak JY, Kim SH, Oh SJ, Zang DY, Lee S, Park HL, Jo DJ, Shin JS, Do YR, Kim DW, Lee JI. Noh H, et al. Among authors: lee ji, lee s. Cancer Med. 2018 May;7(5):1766-1773. doi: 10.1002/cam4.1436. Epub 2018 Mar 25. Cancer Med. 2018. PMID: 29577681 Free PMC article. Clinical Trial.

2

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, Cho DJ, Kim DW, Lee JI. Noh H, et al. Among authors: lee ji. Leuk Lymphoma. 2016 Aug;57(8):1856-64. doi: 10.3109/10428194.2015.1113278. Epub 2015 Dec 15. Leuk Lymphoma. 2016. PMID: 26666371 Clinical Trial.

3

Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.

Shin H, Choi SY, Kee KM, Kim SH, Yang SY, Jung SY, Noh H, Zang DY, Kim DW, Lee JI. Shin H, et al. Among authors: lee ji. Int J Hematol. 2020 Mar;111(3):417-426. doi: 10.1007/s12185-019-02805-9. Epub 2019 Dec 20. Int J Hematol. 2020. PMID: 31863342

4

Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia.

Lee J, Jung SY, Choi MY, Park JS, Park SK, Lim SA, Cho KH, Oh SY, Ha J, Kim DW, Lee J. Lee J, et al. J Clin Pharm Ther. 2020 Oct;45(5):1006-1013. doi: 10.1111/jcpt.13124. Epub 2020 Feb 5. J Clin Pharm Ther. 2020. PMID: 32022312

5

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.

Song HY, Noh H, Choi SY, Lee SE, Kim SH, Kee KM, Yoo HL, Lee MY, Kang KH, Suh JH, Yang SY, Jang EJ, Lee JI, Kim DW. Song HY, et al. Among authors: lee my, lee ji, lee se. Cancer Med. 2018 Oct;7(10):5107-5117. doi: 10.1002/cam4.1753. Epub 2018 Aug 31. Cancer Med. 2018. PMID: 30171671 Free PMC article.

6

Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.

Shin H, Ha JE, Zang DY, Kim SH, Do YR, Lee WS, Kim DW, Lee JI. Shin H, et al. Among authors: lee ws, lee ji. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e521-e529. doi: 10.1016/j.clml.2021.01.020. Epub 2021 Feb 2. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33632667

7

Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.

Jung SY, Lee SH, Lee SY, Yang S, Noh H, Chung EK, Lee JI. Jung SY, et al. Among authors: lee sh, lee sy, lee ji. Crit Care. 2017 Dec 20;21(1):319. doi: 10.1186/s13054-017-1916-6. Crit Care. 2017. PMID: 29262831 Free PMC article. Review.

8

Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.

Jung SY, Yug JS, Clarke JM, Bauer TM, Keedy VL, Hwang S, Kim SJ, Chung EK, Lee JI. Jung SY, et al. Among authors: lee ji. Cancer Chemother Pharmacol. 2020 Jan;85(1):173-183. doi: 10.1007/s00280-019-03979-z. Epub 2019 Oct 30. Cancer Chemother Pharmacol. 2020. PMID: 31673825

9

Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.

Jung SY, Hwang S, Clarke JM, Bauer TM, Keedy VL, Lee H, Park N, Kim SJ, Lee JI. Jung SY, et al. Among authors: lee h, lee ji. Invest New Drugs. 2020 Jun;38(3):812-820. doi: 10.1007/s10637-019-00835-y. Epub 2019 Jul 13. Invest New Drugs. 2020. PMID: 31300967 Clinical Trial.

10

Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis.

Jung SY, Park JH, Baek MJ, Kim GH, Kim J, Zheng HM, Kim JM, Kang IM, Kim DD, Lee JI. Jung SY, et al. Among authors: lee ji. Int J Pharm. 2020 Mar 30;578:119103. doi: 10.1016/j.ijpharm.2020.119103. Epub 2020 Feb 7. Int J Pharm. 2020. PMID: 32036008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,006 results

Search Page